



## Clinical trial results:

**The H10 EORTC/GELA/IIL randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma.**

### Summary

EudraCT number	2005-002765-37
Trial protocol	NL BE DK FR IT SK
Global end of trial date	09 January 2015

### Results information

Result version number	v1 (current)
This version publication date	10 August 2016
First version publication date	10 August 2016
Summary attachment (see zip file)	Trial design (20051_study design_before_after amendment.pptx)

### Trial information

#### Trial identification

Sponsor protocol code	20051
-----------------------	-------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00433433
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	European Organisation for Research and Treatment of Cancer
Sponsor organisation address	Avenue E. Mounier 83/11, Brussels, Belgium, 1200
Public contact	Project, Budget and Regulatory Dept, European Organisation for Research and Treatment of Cancer, +32 27441062, regulatory@eortc.be
Scientific contact	Project, Budget and Regulatory Dept, European Organisation for Research and Treatment of Cancer, +32 27441062, regulatory@eortc.be

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 January 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 June 2014
Global end of trial reached?	Yes
Global end of trial date	09 January 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective is to evaluate whether chemotherapy alone is as effective -but less toxic-, as combined modality treatment in terms of progression-free survival (PFS), in patients with stages I/II Hodgkin's lymphoma who are FDG-PET scan negative after two cycles of ABVD. This question will be addressed in the group of patients with favorable stages I/II disease as well as in those with unfavorable stages I/II disease.

A secondary objective is to evaluate whether early change of chemotherapy from ABVD to escalated BEACOPP improves the progression-free survival of patients who are FDG-PET-positive after two cycles of ABVD, as compared with those who continue on standard ABVD in both favorable as well as unfavorable subsets of patients.

Protection of trial subjects:

The responsible investigator has ensured that this study has been conducted in agreement with either the Declaration of Helsinki (Tokyo, Venice, Hong Kong, Somerset West and Edinburgh amendments) and/or the laws and regulations of the country, whichever provides the greatest protection of the patient.

The protocol has been written, and the study has been conducted according to the ICH Harmonized Tripartite Guideline on Good Clinical Practice (ICH-GCP).

The protocol has been approved by the competent ethics committee(s) as required by the applicable national legislation.

Background therapy:

All randomized patients (standard and experimental arms), in both trial subsets (Favorable and Unfavorable), will be administered two cycles of ABVD (Doxorubicin 25 mg/m<sup>2</sup> i.v., Bleomycin 10 mg/m<sup>2</sup> i.v./i.m., Vinblastine 6 mg/m<sup>2</sup> i.v., Dacarbazine 375 mg/m<sup>2</sup> i.v. at day 1 and 15 of each cycle) and will subsequently have a FDG-PET scan, together with a conventional restaging (chest X-ray and CT-thorax).

Evidence for comparator:

Standard treatment for patients with early stage Hodgkin lymphoma, with favorable or unfavorable prognosis, consists of chemotherapy (mainly ABVD) followed by radiotherapy.

Fermé C, Eghbali H, Meerwaldt JH, et al: Chemotherapy plus involved-field radiation in early stage Hodgkin's disease. N Engl J Med 357:1916-1927, 2007

Engert A, Plutschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010

Actual start date of recruitment	23 November 2006
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy, Scientific research
Long term follow-up duration	20 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Netherlands: 332
Country: Number of subjects enrolled	Slovakia: 15
Country: Number of subjects enrolled	Belgium: 162
Country: Number of subjects enrolled	Denmark: 31
Country: Number of subjects enrolled	France: 970
Country: Number of subjects enrolled	Italy: 407
Country: Number of subjects enrolled	Croatia: 20
Country: Number of subjects enrolled	Switzerland: 13
Worldwide total number of subjects	1950
EEA total number of subjects	1937

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	73
Adults (18-64 years)	1843
From 65 to 84 years	34
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 1950 patients were randomized between 23rd November 2006 and 22nd June 2011 in 158 institutions from 8 countries. Two additional patients were randomized but no informed consent was found (patients 62, 1192); these two patients are thus not reported.

### Pre-assignment

Screening details:

Histologically confirmed Hodgkin's lymphoma (HL), except for nodular, lymphocyte predominant subtype (nodular paragranuloma)

Supradiaphragmatic Ann Arbor clinical stage I or II

Previously untreated

Age 15-70 years

WHO performance 0-3

FDG-PET scan prospectively planned after two cycles of ABVD in all patients

Informed consent

### Period 1

Period 1 title	Randomization
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Favorable - Standard
------------------	----------------------

Arm description:

ABVD x 2 cycles (28 days each cycle)

Arm type	Active comparator
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use

Dosage and administration details:

Bleomycin 10 mg/m<sup>2</sup> i.v./i.m. day 1 and 15

Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use

Dosage and administration details:

Doxorubicin 25 mg/m<sup>2</sup> i.v. day 1 and 15

Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use

Dosage and administration details:

Vinblastine 6 mg/m<sup>2</sup> i.v. day 1 and 15

Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Favorable - Experimental
Arm description:	
ABVD x 2 cycles (28 days each cycle)	
Arm type	Experimental
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Unfavorable - Standard
Arm description:	
ABVD x 2 cycles (28 days each cycle)	
Arm type	Active comparator
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	

Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Unfavorable - Experimental
Arm description:	
ABVD x 2 cycles (28 days each cycle)	
Arm type	Experimental
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use

---

**Dosage and administration details:**Dacarbazine 375 mg/m<sup>2</sup> i.v. day 1 and 15

<b>Number of subjects in period 1</b>	<b>Favorable - Standard</b>	<b>Favorable - Experimental</b>	<b>Unfavorable - Standard</b>
Started	375	379	597
Completed	371	376	583
Not completed	4	3	14
Adverse event, serious fatal	-	-	1
Physician decision	-	-	3
Lost to follow-up	-	-	2
Adverse event, non-fatal	-	-	1
Protocol deviation	4	3	7

<b>Number of subjects in period 1</b>	<b>Unfavorable - Experimental</b>
Started	599
Completed	595
Not completed	4
Adverse event, serious fatal	1
Physician decision	-
Lost to follow-up	1
Adverse event, non-fatal	-
Protocol deviation	2

---

**Period 2**

Period 2 title	PET after 2 cycles ABVD
Is this the baseline period?	Yes <sup>[1]</sup>
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Favorable - Standard - PET negative
Arm description:	
ABVD x 1 cycle (28 days) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions)	
Arm type	Active comparator
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Favorable - Experimental - PET negative
Arm description:	
ABVD x 2 cycles (28 days each cycle) without further RT	
Arm type	Experimental
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	



Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Unfavorable - Standard - PET negative
Arm description:	
ABVDx2 cycles (28 days each cycle)+ IN-RT 30Gy (+boost 6Gy to residual lesions).	
Arm type	Active comparator
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Unfavorable - Experimental - PET negative
Arm description:	
ABVDx 4 cycles (28 days each cycle), without RT	
Arm type	Experimental

Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Standard - PET positive
Arm description:	
Favorable : ABVDx1 cycles (28 days each cycle) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions)	
Unfavorable: ABVDx2 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).	
Arm type	Active comparator
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection

Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
<b>Arm title</b>	Experimental - PET positive
Arm description:	
escalated BEACOPP x 2 cycles (21 days each cycle) + INRT30Gy (+boost 6Gy to residual lesions).	
Arm type	Experimental
Investigational medicinal product name	Cyclophosphamide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Cyclophosphamide 1250 mg/m2 i.v. day 1	
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 35 mg/m2 i.v. day 1	
Investigational medicinal product name	Vincristine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 8	
Investigational medicinal product name	Etoposide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Etoposide 200 mg/m2 i.v. day 1 to 3	

Investigational medicinal product name	Procacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Procabazine 100 mg/m2 orally day 1 to 7	
Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Prednisone 40 mg/m2 orally day 1 to 14	
<b>Arm title</b>	Favorable - PET negative (after amendment 2010)
Arm description:	
ABVD x 1 cycle (28 days) + IN-RT 30GY (+boost 6GY to residual lesions).	
Arm type	Not for comparison
Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	
<b>Arm title</b>	Unfavorable - PET negative (after amendment 2010)
Arm description:	
ABVD x 2 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).	
Arm type	Not for comparison

Investigational medicinal product name	Doxorubicin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Doxorubicin 25 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Bleomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15	
Investigational medicinal product name	Vinblastine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Vinblastine 6 mg/m2 i.v. day 1 and 15	
Investigational medicinal product name	Dacarbazine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use
Dosage and administration details:	
Dacarbazine 375 mg/m2 i.v. day 1 and 15	

Notes:

[1] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Period 1 is the period starting at randomization and covers the two first cycles of ABVD. The 3 groups of interest (1) Favorable - PET negative 2) Unfavorable - PET negative 3) PET positive) can only be defined after the PET performed after 2 cycles ABVD, that is, at period 2.

<b>Number of subjects in period 2<sup>[2]</sup></b>	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative
Started	227	238	292
Completed	220	228	276
Not completed	7	10	16
Patient refusal	1	2	5
Adverse event, serious fatal	-	-	-
Physician decision	3	6	5
Adverse event, non-fatal	-	1	1
Unknown reason	1	-	1
Patient move	1	-	-
Protocol deviation	1	1	3
Lack of efficacy	-	-	1

Number of subjects in period 2 <sup>[2]</sup>	Unfavorable - Experimental - PET negative	Standard - PET positive	Experimental - PET positive
Started	302	192	169
Completed	284	164	139
Not completed	18	28	30
Patient refusal	5	2	10
Adverse event, serious fatal	1	-	-
Physician decision	8	13	18
Adverse event, non-fatal	4	-	-
Unknown reason	-	-	-
Patient move	-	-	-
Protocol deviation	-	1	2
Lack of efficacy	-	12	-

Number of subjects in period 2 <sup>[2]</sup>	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)
Started	185	320
Completed	179	309
Not completed	6	11
Patient refusal	-	2
Adverse event, serious fatal	-	-
Physician decision	2	6
Adverse event, non-fatal	2	2
Unknown reason	2	-
Patient move	-	-
Protocol deviation	-	-
Lack of efficacy	-	1

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Of the total 1950 randomized patients, 4 patients did not start ABVD treatment or no information, 7 patients did not complete the 2 first ABVD cycles and 14 patients completed these 2 ABVD cycles but did not do the subsequent PET scan, thus leaving 1925 patients classified in the 3 groups of interest: 1) Favorable - PET negative 2) Unfavorable - PET negative 3) PET positive. 21 of these patients are included in the adverse events section as they received the background therapy (2 cycles ABVD).

## Baseline characteristics

### Reporting groups

Reporting group title	Favorable - Standard - PET negative
Reporting group description: ABVD x 1 cycle (28 days) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions)	
Reporting group title	Favorable - Experimental - PET negative
Reporting group description: ABVD x 2 cycles (28 days each cycle) without further RT	
Reporting group title	Unfavorable - Standard - PET negative
Reporting group description: ABVDx2 cycles (28 days each cycle)+ IN-RT 30Gy (+boost 6Gy to residual lesions).	
Reporting group title	Unfavorable - Experimental - PET negative
Reporting group description: ABVDx 4 cycles (28 days each cycle), without RT	
Reporting group title	Standard - PET positive
Reporting group description: Favorable : ABVDx1 cycles (28 days each cycle) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions) Unfavorable: ABVDx2 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).	
Reporting group title	Experimental - PET positive
Reporting group description: escalated BEACOPP x 2 cycles (21 days each cycle) + INRT30Gy (+boost 6Gy to residual lesions).	
Reporting group title	Favorable - PET negative (after amendment 2010)
Reporting group description: ABVD x 1 cycle (28 days) + IN-RT 30GY (+boost 6GY to residual lesions).	
Reporting group title	Unfavorable - PET negative (after amendment 2010)
Reporting group description: ABVD x 2 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).	

Reporting group values	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative
Number of subjects	227	238	292
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
median	31	30	32
full range (min-max)	15 to 49	15 to 49	15 to 70

Gender categorical			
Units: Subjects			
Female	96	124	151
Male	131	114	141
Risk group			
Favorable/unfavorable, as collected in CRF.			
Units: Subjects			
Favorable	224	235	12
Unfavorable	3	3	280
Ann Arbor stage			
Units: Subjects			
Stage I	65	76	56
Stage II	161	162	232
Stage III	1	0	2
Stage IV	0	0	2
Baseline PET available (yes/no)			
Units: Subjects			
No	8	11	14
Yes	219	227	278
PET after 2 cycles ABVD (local assessment)			
Units: Subjects			
Negative	221	234	279
Positive	6	3	13
Missing	0	1	0
PET after 2 cycles ABVD (central review)			
Units: Subjects			
Negative	164	181	222
Positive	3	2	7
Unknown/missing	60	55	63
Histology			
Units: Subjects			
Nodular Lymphocyte Predominant	0	2	0
Nodular Sclerosis	175	175	252
Mixed Cellularity	36	45	30
Lymphocyte Depletion	2	0	1
Lymphocyte Rich Classical	11	11	4
Other	3	5	5
WHO performance status			
Units: Subjects			
WHO PS 0	209	230	239
WHO PS 1	18	7	51
WHO PS 2	0	1	2
WHO PS 3	0	0	0

Reporting group values	Unfavorable - Experimental - PET negative	Standard - PET positive	Experimental - PET positive
Number of subjects	302	192	169
Age categorical			
Units: Subjects			
In utero			



Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years median full range (min-max)	31 16 to 70	30 15 to 66	30 15 to 70
Gender categorical Units: Subjects			
Female	165	94	74
Male	137	98	95
Risk group			
Favorable/unfavorable, as collected in CRF.			
Units: Subjects			
Favorable	12	57	47
Unfavorable	290	135	122
Ann Arbor stage Units: Subjects			
Stage I	59	47	31
Stage II	243	144	136
Stage III	0	1	2
Stage IV	0	0	0
Baseline PET available (yes/no) Units: Subjects			
No	15	14	9
Yes	287	178	160
PET after 2 cycles ABVD (local assessment) Units: Subjects			
Negative	293	25	17
Positive	9	167	152
Missing	0	0	0
PET after 2 cycles ABVD (central review) Units: Subjects			
Negative	227	13	6
Positive	6	117	127
Unknown/missing	69	62	36
Histology Units: Subjects			
Nodular Lymphocyte Predominant	0	0	0
Nodular Sclerosis	249	148	135
Mixed Cellularity	29	20	15
Lymphocyte Depletion	3	2	2
Lymphocyte Rich Classical	9	13	7
Other	12	9	10

WHO performance status			
Units: Subjects			
WHO PS 0	239	147	125
WHO PS 1	60	44	41
WHO PS 2	3	1	3
WHO PS 3	0	0	0

Reporting group values	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)	Total
Number of subjects	185	320	1925
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
median	28	30	
full range (min-max)	16 to 49	16 to 68	-
Gender categorical			
Units: Subjects			
Female	101	181	986
Male	84	139	939
Risk group			
Favorable/unfavorable, as collected in CRF.			
Units: Subjects			
Favorable	185	12	784
Unfavorable	0	308	1141
Ann Arbor stage			
Units: Subjects			
Stage I	50	44	428
Stage II	134	276	1488
Stage III	1	0	7
Stage IV	0	0	2
Baseline PET available (yes/no)			
Units: Subjects			
No	5	8	84
Yes	180	312	1841
PET after 2 cycles ABVD (local assessment)			
Units: Subjects			
Negative	178	307	1554
Positive	6	13	369
Missing	1	0	2

PET after 2 cycles ABVD (central review)			
Units: Subjects			
Negative	122	243	1178
Positive	4	4	270
Unknown/missing	59	73	477
Histology			
Units: Subjects			
Nodular Lymphocyte Predominant	0	1	3
Nodular Sclerosis	149	285	1568
Mixed Cellularity	23	23	221
Lymphocyte Depletion	2	3	15
Lymphocyte Rich Classical	8	3	66
Other	3	5	52
WHO performance status			
Units: Subjects			
WHO PS 0	169	253	1611
WHO PS 1	14	63	298
WHO PS 2	2	3	15
WHO PS 3	0	1	1

## End points

### End points reporting groups

Reporting group title	Favorable - Standard
Reporting group description: ABVD x 2 cycles (28 days each cycle)	
Reporting group title	Favorable - Experimental
Reporting group description: ABVD x 2 cycles (28 days each cycle)	
Reporting group title	Unfavorable - Standard
Reporting group description: ABVD x 2 cycles (28 days each cycle)	
Reporting group title	Unfavorable - Experimental
Reporting group description: ABVD x 2 cycles (28 days each cycle)	
Reporting group title	Favorable - Standard - PET negative
Reporting group description: ABVD x 1 cycle (28 days) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions)	
Reporting group title	Favorable - Experimental - PET negative
Reporting group description: ABVD x 2 cycles (28 days each cycle) without further RT	
Reporting group title	Unfavorable - Standard - PET negative
Reporting group description: ABVDx2 cycles (28 days each cycle)+ IN-RT 30Gy (+boost 6Gy to residual lesions).	
Reporting group title	Unfavorable - Experimental - PET negative
Reporting group description: ABVDx 4 cycles (28 days each cycle), without RT	
Reporting group title	Standard - PET positive
Reporting group description: Favorable : ABVDx1 cycles (28 days each cycle) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions) Unfavorable: ABVDx2 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).	
Reporting group title	Experimental - PET positive
Reporting group description: escalated BEACOPP x 2 cycles (21 days each cycle) + INRT30Gy (+boost 6Gy to residual lesions).	
Reporting group title	Favorable - PET negative (after amendment 2010)
Reporting group description: ABVD x 1 cycle (28 days) + IN-RT 30GY (+boost 6GY to residual lesions).	
Reporting group title	Unfavorable - PET negative (after amendment 2010)
Reporting group description: ABVD x 2 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).	

### Primary: PFS rate at 5 years (%) - Study population

End point title	PFS rate at 5 years (%) - Study population <sup>[1]</sup>
End point description: Progression free survival (PFS) is counted from the date of randomization to the date of documentation of objective progression or death (from any cause), whichever occurs first. Patients alive and free of progression are censored at the date of last follow-up.	
Endpoint analyzed in the study population: all patients randomized in the trial, excluding patients who	

have not completed the 2 first ABVD cycles, or for whom no subsequent PET scan has been performed.

End point type	Primary
----------------	---------

End point timeframe:

Disease status evaluated after 2 cycles ABVD, at end of chemotherapy; at end of radiotherapy; at months 4, 6 and 9 during year 1 after end of treatment; every 3 months during year 2; every 6 months during years 3 and 4; yearly at years 5 to 10.

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint at 5 years is not defined for arms where duration of follow-up is too short.

End point values	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative	Unfavorable - Experimental - PET negative
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	227	238	292	302
Units: Percentage				
number (not applicable)	99	87.1	92.1	89.6

End point values	Standard - PET positive	Experimental - PET positive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	192	169		
Units: Percentage				
number (not applicable)	77.4	90.6		

## Statistical analyses

<b>Statistical analysis title</b>	Comparison Favorable PET negative: Exp vs. Std
Comparison groups	Favorable - Experimental - PET negative v Favorable - Standard - PET negative
Number of subjects included in analysis	465
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.986 [2]
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	15.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.79
upper limit	66.07

Notes:

[2] - p-value for non-inferiority test

Non-inferiority margin: Hazard Ratio=3.2

Based on Cox model and Wald test - Asymptotically equivalent to Logrank test

<b>Statistical analysis title</b>	Comparison Unfavorable PET negative: Exp vs. Std
Comparison groups	Unfavorable - Standard - PET negative v Unfavorable -

	Experimental - PET negative
Number of subjects included in analysis	594
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.908 <sup>[3]</sup>
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	2.5

Notes:

[3] - p-value for non-inferiority test

Non-inferiority margin: Hazard Ratio=2.1

Based on Cox model and Wald test - Asymptotically equivalent to Logrank test

<b>Statistical analysis title</b>	Comparison PET positive: Exp vs. Std
Comparison groups	Standard - PET positive v Experimental - PET positive
Number of subjects included in analysis	361
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.23
upper limit	0.74

## Secondary: EFS rate at 5 years (%) - Study population

End point title	EFS rate at 5 years (%) - Study population <sup>[4]</sup>
-----------------	-----------------------------------------------------------

End point description:

Event free survival (EFS) is counted from the date of randomization to the date of occurrence of death, objective progression, premature discontinuation of protocol therapy, or start of off protocol anti-cancer therapy. Patients without documented event at the time of the analysis are censored at the date of last follow-up. It was agreed by the DRC that off protocol anti-cancer therapy was to be restricted to therapy for HL; therapy for second malignancies was not considered as an event for EFS by the DRC.

Endpoint analyzed in the study population: all patients randomized in the trial, excluding patients who have not completed the 2 first ABVD cycles, or for whom no subsequent PET scan has been performed.

End point type	Secondary
----------------	-----------

End point timeframe:

Disease status evaluated after 2 cycles ABVD, at end of chemotherapy; at end of radiotherapy; at months 4, 6 and 9 during year 1 after end of treatment; every 3 months during year 2; every 6 months during years 3 and 4; yearly at years 5 to 10.

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: This endpoint at 5 years is not defined for arms where duration of follow-up is too short.

<b>End point values</b>	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative	Unfavorable - Experimental - PET negative
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	227	238	292	302
Units: Percentage				
number (not applicable)	96.3	82.5	87	82.7

<b>End point values</b>	Standard - PET positive	Experimental - PET positive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	192	169		
Units: Percentage				
number (not applicable)	71	76.5		

### Statistical analyses

<b>Statistical analysis title</b>	Comparison Favorable PET negative: Exp vs. Std
Comparison groups	Favorable - Standard - PET negative v Favorable - Experimental - PET negative
Number of subjects included in analysis	465
Analysis specification	Pre-specified
Analysis type	other <sup>[5]</sup>
Parameter estimate	Hazard ratio (HR)
Point estimate	5.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	11.36

Notes:

[5] - No inferential test as non-inferiority margin for EFS not pre-specified.

<b>Statistical analysis title</b>	Comparison Unfavorable PET negative: Exp vs. Std
Comparison groups	Unfavorable - Standard - PET negative v Unfavorable - Experimental - PET negative
Number of subjects included in analysis	594
Analysis specification	Pre-specified
Analysis type	other <sup>[6]</sup>
Parameter estimate	Hazard ratio (HR)
Point estimate	1.43

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	2.17

Notes:

[6] - No inferential test as non-inferiority margin for EFS not pre-specified.

<b>Statistical analysis title</b>	Comparison PET positive: Exp vs. Std
Comparison groups	Standard - PET positive v Experimental - PET positive
Number of subjects included in analysis	361
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.417
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.27

## Secondary: OS rate at 5 years (%) - Study population

End point title	OS rate at 5 years (%) - Study population <sup>[7]</sup>
-----------------	----------------------------------------------------------

End point description:

Overall survival (OS) is counted from the date of randomization to the date of death (from any cause), whichever occurs first. Patients alive and free of progression are censored at the date of last follow-up.

Endpoint analyzed in the study population: all patients randomized in the trial, excluding patients who have not completed the 2 first ABVD cycles, or for whom no subsequent PET scan has been performed.

End point type	Secondary
----------------	-----------

End point timeframe:

Overall survival is counted from the date of randomization to the date of death (from any cause), whichever occurs first. Patients alive and free of progression are censored at the date of last follow-up.

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint at 5 years is not defined for arms where duration of follow-up is too short.

End point values	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative	Unfavorable - Experimental - PET negative
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	227	238	292	302
Units: Percentage				
number (not applicable)	100	99.6	96.7	99.3



<b>End point values</b>	Standard - PET positive	Experimental - PET positive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	192	169		
Units: Percentage				
number (not applicable)	89.3	96		

## Statistical analyses

<b>Statistical analysis title</b>	Comparison PET positive: Exp vs. Std
Comparison groups	Standard - PET positive v Experimental - PET positive
Number of subjects included in analysis	361
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.062
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	1.07

<b>Statistical analysis title</b>	Comparison Unfavorable PET negative: Exp vs. Std
Comparison groups	Unfavorable - Standard - PET negative v Unfavorable - Experimental - PET negative
Number of subjects included in analysis	594
Analysis specification	Pre-specified
Analysis type	other <sup>[8]</sup>
Parameter estimate	Hazard ratio (HR)
Point estimate	0.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.21
upper limit	1.58

Notes:

[8] - No inferential test as non-inferiority margin for OS not pre-specified.

## Secondary: PFS rate at 5 years (%) - Per-protocol population

End point title	PFS rate at 5 years (%) - Per-protocol population <sup>[9]</sup>
-----------------	------------------------------------------------------------------

**End point description:**

Progression free survival (PFS) is counted from the date of randomization to the date of documentation of objective progression or death (from any cause), whichever occurs first. Patients alive and free of progression are censored at the date of last follow-up.

Endpoint analyzed in the per-protocol population: all "study" patients who were eligible for the trial, excluding patients who were later found to be in the wrong risk group (favorable/unfavorable; PET negative/positive).

End point type	Secondary
----------------	-----------

**End point timeframe:**

Disease status evaluated after 2 cycles ABVD, at end of chemotherapy; at end of radiotherapy; at months 4, 6 and 9 during year 1 after end of treatment; every 3 months during year 2; every 6 months during years 3 and 4; yearly at years 5 to 10.

**Notes:**

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint at 5 years is not defined for arms where duration of follow-up is too short.

End point values	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative	Unfavorable - Experimental - PET negative
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	221	232	268	289
Units: Percentage				
number (not applicable)	98.9	88.6	91.7	89.8

End point values	Standard - PET positive	Experimental - PET positive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	172	159		
Units: Percentage				
number (not applicable)	75.9	91.9		

**Statistical analyses**

Statistical analysis title	Comparison Favorable PET negative: Exp vs. Std
Comparison groups	Favorable - Standard - PET negative v Favorable - Experimental - PET negative
Number of subjects included in analysis	453
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.976 <sup>[10]</sup>
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	13.68
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.25
upper limit	57.55

Notes:

[10] - p-value for non-inferiority test

Non-inferiority margin: Hazard Ratio=3.2

Based on Cox model and Wald test - Asymptotically equivalent to Logrank test

<b>Statistical analysis title</b>	Comparison Unfavorable PET negative: Exp vs. Std
Comparison groups	Unfavorable - Standard - PET negative v Unfavorable - Experimental - PET negative
Number of subjects included in analysis	557
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.948 <sup>[11]</sup>
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	2.31

Notes:

[11] - p-value for non-inferiority test

Non-inferiority margin: Hazard Ratio=2.1

Based on Cox model and Wald test - Asymptotically equivalent to Logrank test

<b>Statistical analysis title</b>	Comparison PET positive: Exp vs. Std
Comparison groups	Standard - PET positive v Experimental - PET positive
Number of subjects included in analysis	331
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.18
upper limit	0.62

## Secondary: EFS rate at 5 years (%) - Per-protocol population

End point title	EFS rate at 5 years (%) - Per-protocol population <sup>[12]</sup>
End point description:	
Event free survival (EFS) is counted from the date of randomization to the date of occurrence of death, objective progression, premature discontinuation of protocol therapy, or start of off protocol anti-cancer therapy. Patients without documented event at the time of the analysis are censored at the date of last follow-up. It was agreed by the DRC that off protocol anti-cancer therapy was to be restricted to therapy for HL; therapy for second malignancies was not considered as an event for EFS by the DRC.	
Endpoint analyzed in the per-protocol population: all "study" patients who were eligible for the trial, excluding patients who were later found to be in the wrong risk group (favorable/unfavorable; PET negative/positive).	
End point type	Secondary

End point timeframe:

Disease status evaluated after 2 cycles ABVD, at end of chemotherapy; at end of radiotherapy; at months 4, 6 and 9 during year 1 after end of treatment; every 3 months during year 2; every 6 months during years 3 and 4; yearly at years 5 to 10.

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint at 5 years is not defined for arms where duration of follow-up is too short.

End point values	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative	Unfavorable - Experimental - PET negative
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	221	232	268	289
Units: Percentage				
number (not applicable)	96.7	84.3	87.6	83.6

End point values	Standard - PET positive	Experimental - PET positive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	172	159		
Units: Percentage				
number (not applicable)	71.7	78.8		

## Statistical analyses

Statistical analysis title	Comparison Favorable PET negative: Exp vs. Std
Comparison groups	Favorable - Standard - PET negative v Favorable - Experimental - PET negative
Number of subjects included in analysis	453
Analysis specification	Pre-specified
Analysis type	other <sup>[13]</sup>
Parameter estimate	Hazard ratio (HR)
Point estimate	5.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.38
upper limit	11.98

Notes:

[13] - No inferential test as non-inferiority margin for EFS not pre-specified.

Statistical analysis title	Comparison Unfavorable PET negative: Exp vs. Std
Comparison groups	Unfavorable - Standard - PET negative v Unfavorable - Experimental - PET negative

Number of subjects included in analysis	557
Analysis specification	Pre-specified
Analysis type	other <sup>[14]</sup>
Parameter estimate	Hazard ratio (HR)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	2.2

Notes:

[14] - No inferential test as non-inferiority margin for EFS not pre-specified.

<b>Statistical analysis title</b>	Comparison PET positive: Exp vs. Std
Comparison groups	Standard - PET positive v Experimental - PET positive
Number of subjects included in analysis	331
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.262
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.21

## Secondary: OS rate at 5 years (%) - Per-protocol population

End point title	OS rate at 5 years (%) - Per-protocol population <sup>[15]</sup>
-----------------	------------------------------------------------------------------

End point description:

Overall survival (OS) is counted from the date of randomization to the date of death (from any cause), whichever occurs first. Patients alive and free of progression are censored at the date of last follow-up.

Endpoint analyzed in the per-protocol population: all "study" patients who were eligible for the trial, excluding patients who were later found to be in the wrong risk group (favorable/unfavorable; PET negative/positive).

End point type	Secondary
----------------	-----------

End point timeframe:

Overall survival is counted from the date of randomization to the date of death (from any cause), whichever occurs first.

Patients alive and free of progression are censored at the date of last follow-up.

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint at 5 years is not defined for arms where duration of follow-up is too short.

<b>End point values</b>	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative	Unfavorable - Experimental - PET negative
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	221	232	268	289
Units: Percentage				
number (not applicable)	100	99.6	96.4	98.2

<b>End point values</b>	Standard - PET positive	Experimental - PET positive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	172	159		
Units: Percentage				
number (not applicable)	89.3	95.7		

### Statistical analyses

<b>Statistical analysis title</b>	Comparison PET positive: Exp vs. Std
Comparison groups	Standard - PET positive v Experimental - PET positive
Number of subjects included in analysis	331
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.097
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	1.16

<b>Statistical analysis title</b>	Comparison Unfavorable PET negative: Exp vs. Std
Comparison groups	Unfavorable - Standard - PET negative v Unfavorable - Experimental - PET negative
Number of subjects included in analysis	557
Analysis specification	Pre-specified
Analysis type	other <sup>[16]</sup>
Parameter estimate	Hazard ratio (HR)
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.16
upper limit	1.35

Notes:

[16] - No inferential test as non-inferiority margin for OS not pre-specified.

### Secondary: PFS rate at 3 years (%) - Study population

End point title	PFS rate at 3 years (%) - Study population <sup>[17]</sup>
-----------------	------------------------------------------------------------

End point description:

Progression free survival (PFS) is counted from the date of randomization to the date of documentation of objective progression or death (from any cause), whichever occurs first.

Patients alive and free of progression are censored at the date of last follow-up.

Endpoint analyzed in the study population: all patients randomized in the trial, excluding patients who have not completed the 2 first ABVD cycles, or for whom no subsequent PET scan has been performed.

End point type	Secondary
----------------	-----------

End point timeframe:

Disease status evaluated after 2 cycles ABVD, at end of chemotherapy; at end of radiotherapy; at months 4, 6 and 9 during year 1 after end of treatment; every 3 months during year 2; every 6 months during years 3 and 4; yearly at years 5 to 10.

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint (at 3 years) is not provided for the arms where the same endpoint at 5 years is provided.

End point values	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	320		
Units: Percentage				
number (not applicable)	98.9	95.5		

### Statistical analyses

No statistical analyses for this end point

### Secondary: EFS rate at 3 years (%) - Study population

End point title	EFS rate at 3 years (%) - Study population <sup>[18]</sup>
-----------------	------------------------------------------------------------

End point description:

Event free survival (EFS) is counted from the date of randomization to the date of occurrence of death, objective progression, premature discontinuation of protocol therapy, or start of off protocol anti-cancer therapy. Patients without documented event at the time of the analysis are censored at the date of last follow-up. It was agreed by the DRC that off protocol anti-cancer therapy was to be restricted to therapy for HL; therapy for second malignancies was not considered as an event for EFS by the DRC.

Endpoint analyzed in the study population: all patients randomized in the trial, excluding patients who have not completed the 2 first ABVD cycles, or for whom no subsequent PET scan has been performed.

End point type	Secondary
----------------	-----------

End point timeframe:

Disease status evaluated after 2 cycles ABVD, at end of chemotherapy; at end of radiotherapy; at months 4, 6 and 9 during year 1 after end of treatment; every 3 months during year 2; every 6 months during years 3 and 4; yearly at years 5 to 10.

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint (at 3 years) is not provided for the arms where the same endpoint at 5 years is provided.

End point values	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	320		
Units: Percentage				
number (not applicable)	96.7	93.6		

## Statistical analyses

No statistical analyses for this end point

## Secondary: OS rate at 3 years (%) - Study population

End point title	OS rate at 3 years (%) - Study population <sup>[19]</sup>
End point description:	
Overall survival (OS) is counted from the date of randomization to the date of death (from any cause), whichever occurs first. Patients alive and free of progression are censored at the date of last follow-up.	
Endpoint analyzed in the study population: all patients randomized in the trial, excluding patients who have not completed the 2 first ABVD cycles, or for whom no subsequent PET scan has been performed.	
End point type	Secondary

End point timeframe:

Overall survival is counted from the date of randomization to the date of death (from any cause), whichever occurs first.

Patients alive and free of progression are censored at the date of last follow-up.

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint (at 3 years) is not provided for the arms where the same endpoint at 5 years is provided.

End point values	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	320		
Units: Percentage				
number (not applicable)	100	99.7		

## Statistical analyses





## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events and results of blood tests/ serum chemistry were collected on a CRF to be submitted at pre-specified time-points: before treatment start; after each cycle of CT; at end of CT; at end of RT; during follow-up.

Adverse event reporting additional description:

CRF for AEs contains pre-specified items + additional boxes for all "other" AEs. (Few AEs are reported as "other" and are not reported as not available from the list of SOC). AEs are evaluated using CTC grading, SAEs using MedDra. Non-SAEs has not been collected specifically, therefore all AEs (grade 3 or more) will be reported in non-SAE section.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

### Reporting groups

Reporting group title	Favorable - Standard - PET negative
-----------------------	-------------------------------------

Reporting group description:

ABVD x 3 cycles (28 days each cycle) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions).

Safety population: Patients who started the allocated treatment.

Reporting group title	Favorable - Experimental - PET negative
-----------------------	-----------------------------------------

Reporting group description:

ABVD x 4 cycles (28 days each cycle) without further RT.

Safety population: Patients who started the allocated treatment.

Reporting group title	Unfavorable - Standard - PET negative
-----------------------	---------------------------------------

Reporting group description:

ABVD x 4 cycles (28 days each cycle)+ IN-RT 30Gy (+boost 6Gy to residual lesions).

Safety population: Patients who started the allocated treatment.

Reporting group title	Unfavorable - Experimental - PET negative
-----------------------	-------------------------------------------

Reporting group description:

ABVD x 6 cycles (28 days each cycle), without RT.

Safety population: Patients who started the allocated treatment.

Reporting group title	Standard - PET positive
-----------------------	-------------------------

Reporting group description:

Favorable : ABVDx3 cycles (28 days each cycle) + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions)

Unfavorable: ABVDx4 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).

Safety population: Patients who started the allocated treatment.

Reporting group title	Experimental - PET positive
-----------------------	-----------------------------

Reporting group description:

ABVD x 2 cycles (28 days each cycle) + escalated BEACOPP x 2 cycles (21 days each cycle) + INRT30Gy (+boost 6Gy to residual lesions).

Safety population: Patients who started the allocated treatment.

Reporting group title	Favorable - PET negative (after amendment 2010)
-----------------------	-------------------------------------------------

Reporting group description:

ABVD x 3 cycle (28 days) + IN-RT 30GY (+boost 6GY to residual lesions).

Safety population: Patients who started the allocated treatment.

Reporting group title	Unfavorable - PET negative (after amendment 2010)
-----------------------	---------------------------------------------------

Reporting group description:

ABVD x 4 cycles (28 days each cycle) + IN-RT 30Gy (+boost 6Gy to residual lesions).

Safety population: Patients who started the allocated treatment.

Reporting group title	No PET after 2 cycles
-----------------------	-----------------------

<b>Serious adverse events</b>	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 227 (6.61%)	18 / 238 (7.56%)	38 / 292 (13.01%)
number of deaths (all causes)	0	3	10
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	3 / 292 (1.03%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Chills	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	3 / 227 (1.32%)	1 / 238 (0.42%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	2 / 3	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sense of oppression	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Contrast media allergy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Prostatitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus genital	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infiltration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal pain	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Painful respiration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	4 / 292 (1.37%)
occurrences causally related to treatment / all	1 / 1	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	5 / 292 (1.71%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary toxicity	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety	Additional description: From pharmacovigilance database.		



subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Maternal exposure before pregnancy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis chemical	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fistula	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation dysphagia	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation oesophagitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracardiac thrombus	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-obstructive cardiomyopathy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral venous thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lhermitte's sign	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental impairment	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
Anaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bone marrow failure</b>			
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile bone marrow aplasia</b>			
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Febrile neutropenia</b>			
subjects affected / exposed	3 / 227 (1.32%)	3 / 238 (1.26%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	3 / 3	3 / 3	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Leukopenia</b>			
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Neutropenia</b>			
subjects affected / exposed	2 / 227 (0.88%)	0 / 238 (0.00%)	4 / 292 (1.37%)
occurrences causally related to treatment / all	2 / 2	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancytopenia</b>			
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Thrombocytopenia</b>			
	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Oculogyric crisis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic pseudo-obstruction	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 227 (0.88%)	3 / 238 (1.26%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	2 / 2	3 / 3	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea	Additional description: From pharmacovigilance database.		

subjects affected / exposed	2 / 227 (0.88%)	3 / 238 (1.26%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	2 / 2	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	3 / 238 (1.26%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	1 / 1	3 / 3	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Drug-induced liver injury	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hyperhidrosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria	Additional description: From pharmacovigilance database.		



subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis haemorrhagic	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hyperaldosteronism	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Muscle contracture subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Musculoskeletal pain subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Infections and infestations Anal abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Appendicitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	1 / 238 (0.42%)	2 / 292 (0.68%)
	0 / 0	0 / 1	0 / 2
	0 / 0	0 / 0	0 / 0
Bacterial sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Bronchitis viral subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	1 / 227 (0.44%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Cellulitis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Measles	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle abscess	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis Escherichia coli	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	1 / 238 (0.42%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	2 / 292 (0.68%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Unfavorable - Experimental - PET negative	Standard - PET positive	Experimental - PET positive
Total subjects affected by serious adverse events			
subjects affected / exposed	47 / 302 (15.56%)	17 / 192 (8.85%)	42 / 169 (24.85%)
number of deaths (all causes)	6	18	7
number of deaths resulting from adverse events	1	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



General disorders and administration site conditions			
Asthenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Influenza like illness	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	1 / 169 (0.59%)
	occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	2 / 169 (1.18%)
	occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	6 / 302 (1.99%)	0 / 192 (0.00%)	9 / 169 (5.33%)
	occurrences causally related to treatment / all	5 / 6	0 / 0	8 / 11
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sense of oppression	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders				
Contrast media allergy	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast				

disorders			
Prostatitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus genital	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Chronic obstructive pulmonary disease	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Hypoxia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Interstitial lung disease	Additional description: From pharmacovigilance database.		

subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder	Additional description: From pharmacovigilance database.		
subjects affected / exposed	4 / 302 (1.32%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infiltration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Painful respiration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	4 / 302 (1.32%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	4 / 4	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism	Additional description: From pharmacovigilance database.		

subjects affected / exposed	3 / 302 (0.99%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary toxicity	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	2 / 169 (1.18%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Maternal exposure before pregnancy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonitis chemical subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	1 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Post procedural complication subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
	0 / 0	0 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Post procedural fistula subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
	0 / 0	0 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Radiation dysphagia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
	0 / 0	1 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Radiation oesophagitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
	0 / 0	1 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Angina pectoris subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Cardiac arrest subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	1 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Cardiac failure			
Additional description: From pharmacovigilance database.			

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracardiac thrombus	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-obstructive cardiomyopathy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral venous thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lhermitte's sign	Additional description: From pharmacovigilance database.		



subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental impairment	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	2 / 169 (1.18%)
occurrences causally related to treatment / all	2 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	3 / 169 (1.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile bone marrow aplasia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	4 / 169 (2.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	6 / 302 (1.99%)	0 / 192 (0.00%)	17 / 169 (10.06%)
occurrences causally related to treatment / all	6 / 6	0 / 0	17 / 18
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia	Additional description: From pharmacovigilance database.		

subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	3 / 302 (0.99%)	1 / 192 (0.52%)	3 / 169 (1.78%)
occurrences causally related to treatment / all	6 / 6	1 / 1	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	4 / 169 (2.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	2 / 169 (1.18%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Oculogyric crisis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	1 / 192 (0.52%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	1 / 2	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic pseudo-obstruction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	2 / 192 (1.04%)	3 / 169 (1.78%)
occurrences causally related to treatment / all	0 / 0	2 / 2	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	0 / 192 (0.00%)	3 / 169 (1.78%)
occurrences causally related to treatment / all	2 / 2	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	1 / 192 (0.52%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Drug-induced liver injury	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Hyperhidrosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis haemorrhagic	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Hyperaldosteronism	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	3 / 169 (1.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle contracture	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1

Bronchitis viral	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	1 / 169 (0.59%)
	occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
	occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis	Additional description: From pharmacovigilance database.			
	subjects affected / exposed	1 / 302 (0.33%)	1 / 192 (0.52%)	1 / 169 (0.59%)
	occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter sepsis	Additional description: From pharmacovigilance database.			

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection	Additional description: From pharmacovigilance database.		



subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Measles	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	4 / 302 (1.32%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	2 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis Escherichia coli	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	2 / 169 (1.18%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus	Additional description: From pharmacovigilance database.		
subjects affected / exposed	2 / 302 (0.66%)	1 / 192 (0.52%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	1 / 169 (0.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 302 (0.33%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)	No PET after 2 cycles
Total subjects affected by serious adverse events			
subjects affected / exposed	15 / 185 (8.11%)	31 / 320 (9.69%)	3 / 21 (14.29%)
number of deaths (all causes)	0	1	3
number of deaths resulting from	0	0	2

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jugular vein thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	2 / 320 (0.63%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia	Additional description: From pharmacovigilance database.		

subjects affected / exposed	1 / 185 (0.54%)	6 / 320 (1.88%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 1	4 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sense of oppression	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Contrast media allergy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Prostatitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus genital	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infiltration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Painful respiration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration	Additional description: From pharmacovigilance database.		



subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	1 / 320 (0.31%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Pulmonary toxicity	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Psychiatric disorders			
Anxiety	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Maternal exposure before pregnancy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis chemical	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fistula	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation dysphagia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiation oesophagitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Acute coronary syndrome subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Angina pectoris subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Cardiac arrest subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	1 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Cardiac failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	1 / 21 (4.76%)
	0 / 0	0 / 0	1 / 1
	0 / 0	0 / 0	1 / 1
Coronary artery stenosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
	0 / 0	1 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Intracardiac thrombus subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
	0 / 0	1 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Myocardial infarction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
	0 / 0	1 / 1	0 / 0
	0 / 0	0 / 0	0 / 0
Non-obstructive cardiomyopathy	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral infarction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral venous thrombosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lhermitte's sign	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental impairment	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile bone marrow aplasia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	6 / 185 (3.24%)	5 / 320 (1.56%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	8 / 8	5 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	3 / 320 (0.94%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	1 / 1	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic microangiopathy	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Oculogyric crisis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	2 / 320 (0.63%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fissure	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal inflammation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic pseudo-obstruction	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	1 / 21 (4.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	2 / 320 (0.63%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia	Additional description: From pharmacovigilance database.		



subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders	Additional description: From pharmacovigilance database.		
Drug-induced liver injury	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders	Additional description: From pharmacovigilance database.		
Hyperhidrosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders	Additional description: From pharmacovigilance database.		
Acute kidney injury	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cystitis haemorrhagic subjects affected / exposed	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Haematuria subjects affected / exposed	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Renal failure subjects affected / exposed	Additional description: From pharmacovigilance database.		
	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	1 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Endocrine disorders Hyperaldosteronism subjects affected / exposed	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Bone pain subjects affected / exposed	Additional description: From pharmacovigilance database.		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 0	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Muscle contracture subjects affected / exposed	Additional description: From pharmacovigilance database.		
	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0
Musculoskeletal pain subjects affected / exposed	Additional description: From pharmacovigilance database.		
	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0 / 1	0 / 0	0 / 0
	0 / 0	0 / 0	0 / 0

Infections and infestations			
Anal abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis viral	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site infection	Additional description: From pharmacovigilance database.		

subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Measles	Additional description: From pharmacovigilance database.		
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	3 / 320 (0.94%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis Escherichia coli	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control	Additional description: From pharmacovigilance database.		

subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia	Additional description: From pharmacovigilance database.		
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Favorable - Standard - PET negative	Favorable - Experimental - PET negative	Unfavorable - Standard - PET negative
Total subjects affected by non-serious adverse events			
subjects affected / exposed	148 / 227 (65.20%)	178 / 238 (74.79%)	222 / 292 (76.03%)
Vascular disorders			
Vascular	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	1 / 227 (0.44%)	4 / 238 (1.68%)	11 / 292 (3.77%)
occurrences (all)	3	4	19
Surgical and medical procedures			
Surgery/Intra-operative injury	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Constitutional Symptoms	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	7 / 227 (3.08%)	4 / 238 (1.68%)	10 / 292 (3.42%)
occurrences (all)	9	4	11
Immune system disorders			
Allergy/Immunology	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	1 / 227 (0.44%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences (all)	1	0	1
Reproductive system and breast disorders			



Sexual/Reproductive function alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 227 (0.00%)	1 / 238 (0.42%)	1 / 292 (0.34%)
	0	1	1
Respiratory, thoracic and mediastinal disorders Pulmonary alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	6 / 227 (2.64%)	4 / 238 (1.68%)	24 / 292 (8.22%)
	6	5	27
Investigations Alkaline phosphatase alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)  ANC alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)  Bilirubin alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)  GGT alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)  Platelets alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)  Serum creatinine alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)  SGOT(ASAT)	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
	0	0	0
	Additional description: From clinical database. All AEs (grade 3 or more).		
	127 / 227 (55.95%)	159 / 238 (66.81%)	195 / 292 (66.78%)
	307	402	522
	Additional description: From clinical database. All AEs (grade 3 or more).		
	5 / 227 (2.20%)	5 / 238 (2.10%)	6 / 292 (2.05%)
	54	23	28
	Additional description: From clinical database. All AEs (grade 3 or more).		
	6 / 227 (2.64%)	3 / 238 (1.26%)	9 / 292 (3.08%)
	8	3	17
	Additional description: From clinical database. All AEs (grade 3 or more).		
	1 / 227 (0.44%)	2 / 238 (0.84%)	1 / 292 (0.34%)
	1	3	1
	Additional description: From clinical database. All AEs (grade 3 or more).		
	3 / 227 (1.32%)	4 / 238 (1.68%)	2 / 292 (0.68%)
	52	21	24
	Additional description: From clinical database. All AEs (grade 3 or more).		

alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	0 / 238 (0.00%) 0	1 / 292 (0.34%) 1
SGPT(ALAT)	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	2 / 227 (0.88%) 3	6 / 238 (2.52%) 13	5 / 292 (1.71%) 6
White Blood Cells	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	30 / 227 (13.22%) 47	42 / 238 (17.65%) 67	64 / 292 (21.92%) 112
Cardiac disorders			
Cardiac Arrhythmia	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	0 / 238 (0.00%) 0	0 / 292 (0.00%) 0
Cardiac General	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	0 / 238 (0.00%) 0	2 / 292 (0.68%) 2
Cardiovascular	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	2 / 227 (0.88%) 2	0 / 238 (0.00%) 0	3 / 292 (1.03%) 3
Nervous system disorders			
Neurology	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	2 / 227 (0.88%) 3	3 / 238 (1.26%) 6	5 / 292 (1.71%) 7
Blood and lymphatic system disorders			
Blood/Bone Marrow	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	2 / 227 (0.88%) 2	0 / 238 (0.00%) 0	6 / 292 (2.05%) 6
Febrile neutropenia	Additional description: From clinical database. All AEs (grade 3 or more).		

alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	9 / 227 (3.96%) 11	11 / 238 (4.62%) 13	7 / 292 (2.40%) 7
Hemoglobin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	1 / 227 (0.44%) 1	0 / 238 (0.00%) 0	0 / 292 (0.00%) 0
Lymphatics	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	0 / 238 (0.00%) 0	0 / 292 (0.00%) 0
Ear and labyrinth disorders			
Auditory/Hearing	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	0 / 238 (0.00%) 0	0 / 292 (0.00%) 0
Eye disorders			
Ocular/Visual	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	0 / 238 (0.00%) 0	0 / 292 (0.00%) 0
Gastrointestinal disorders			
Gastrointestinal	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	10 / 227 (4.41%) 10	13 / 238 (5.46%) 15	16 / 292 (5.48%) 17
Hepatobiliary disorders			
Hepatobiliary/Pancreas	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 227 (0.00%) 0	1 / 238 (0.42%) 1	0 / 292 (0.00%) 0
Skin and subcutaneous tissue disorders			
Dermatology/Skin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	11 / 227 (4.85%) 31	10 / 238 (4.20%) 25	14 / 292 (4.79%) 26

Endocrine disorders			
Endocrine	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	1 / 292 (0.34%)
occurrences (all)	0	0	5
Musculoskeletal and connective tissue disorders			
Musculoskeletal/Soft tissue	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 227 (0.00%)	0 / 238 (0.00%)	0 / 292 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Infection	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	5 / 227 (2.20%)	4 / 238 (1.68%)	13 / 292 (4.45%)
occurrences (all)	6	4	14
Metabolism and nutrition disorders			
Albumin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	2 / 227 (0.88%)	2 / 238 (0.84%)	2 / 292 (0.68%)
occurrences (all)	2	2	2
Metabolic/Laboratory	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	1 / 227 (0.44%)	1 / 238 (0.42%)	2 / 292 (0.68%)
occurrences (all)	2	1	2

<b>Non-serious adverse events</b>	Unfavorable - Experimental - PET negative	Standard - PET positive	Experimental - PET positive
Total subjects affected by non-serious adverse events			
subjects affected / exposed	216 / 302 (71.52%)	138 / 192 (71.88%)	142 / 169 (84.02%)
Vascular disorders			
Vascular	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	12 / 302 (3.97%)	1 / 192 (0.52%)	1 / 169 (0.59%)
occurrences (all)	17	1	1
Surgical and medical procedures			
Surgery/Intra-operative injury	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			

subjects affected / exposed occurrences (all)	1 / 302 (0.33%) 1	0 / 192 (0.00%) 0	0 / 169 (0.00%) 0
General disorders and administration site conditions			
Constitutional Symptoms	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	16 / 302 (5.30%) 23	1 / 192 (0.52%) 1	4 / 169 (2.37%) 6
Immune system disorders			
Allergy/Immunology	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	1 / 302 (0.33%) 1	0 / 192 (0.00%) 0	1 / 169 (0.59%) 1
Reproductive system and breast disorders			
Sexual/Reproductive function	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	0 / 302 (0.00%) 0	0 / 192 (0.00%) 0	1 / 169 (0.59%) 1
Respiratory, thoracic and mediastinal disorders			
Pulmonary	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	27 / 302 (8.94%) 34	9 / 192 (4.69%) 9	9 / 169 (5.33%) 9
Investigations			
Alkaline phosphatase	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	0 / 302 (0.00%) 0	0 / 192 (0.00%) 0	1 / 169 (0.59%) 1
ANC	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	184 / 302 (60.93%) 583	122 / 192 (63.54%) 280	124 / 169 (73.37%) 315
Bilirubin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			

subjects affected / exposed	5 / 302 (1.66%)	2 / 192 (1.04%)	4 / 169 (2.37%)
occurrences (all)	29	44	18
GGT	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	14 / 302 (4.64%)	4 / 192 (2.08%)	4 / 169 (2.37%)
occurrences (all)	34	6	4
Platelets	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	5 / 302 (1.66%)	3 / 192 (1.56%)	29 / 169 (17.16%)
occurrences (all)	6	3	43
Serum creatinine	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	3 / 302 (0.99%)	2 / 192 (1.04%)	2 / 169 (1.18%)
occurrences (all)	27	44	16
SGOT(ASAT)	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	1 / 302 (0.33%)	3 / 192 (1.56%)	1 / 169 (0.59%)
occurrences (all)	1	3	1
SGPT(ALAT)	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	6 / 302 (1.99%)	3 / 192 (1.56%)	1 / 169 (0.59%)
occurrences (all)	7	3	2
White Blood Cells	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	63 / 302 (20.86%)	36 / 192 (18.75%)	107 / 169 (63.31%)
occurrences (all)	126	56	221
Cardiac disorders			
Cardiac Arrhythmia	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 302 (0.00%)	0 / 192 (0.00%)	0 / 169 (0.00%)
occurrences (all)	0	0	0
Cardiac General	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			

subjects affected / exposed occurrences (all)	4 / 302 (1.32%) 7	0 / 192 (0.00%) 0	2 / 169 (1.18%) 6
Cardiovascular	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	2 / 302 (0.66%) 2	2 / 192 (1.04%) 2	1 / 169 (0.59%) 1
Nervous system disorders			
Neurology	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	15 / 302 (4.97%) 24	4 / 192 (2.08%) 5	0 / 169 (0.00%) 0
Blood and lymphatic system disorders			
Blood/Bone Marrow	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	4 / 302 (1.32%) 7	1 / 192 (0.52%) 1	14 / 169 (8.28%) 17
Febrile neutropenia	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	15 / 302 (4.97%) 16	6 / 192 (3.13%) 7	36 / 169 (21.30%) 41
Hemoglobin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	2 / 302 (0.66%) 4	4 / 192 (2.08%) 4	9 / 169 (5.33%) 12
Lymphatics	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	3 / 302 (0.99%) 3	0 / 192 (0.00%) 0	0 / 169 (0.00%) 0
Ear and labyrinth disorders			
Auditory/Hearing	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed occurrences (all)	1 / 302 (0.33%) 1	0 / 192 (0.00%) 0	0 / 169 (0.00%) 0
Eye disorders			

Ocular/Visual alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	1 / 302 (0.33%) 1	0 / 192 (0.00%) 0	0 / 169 (0.00%) 0
Gastrointestinal disorders Gastrointestinal alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	11 / 302 (3.64%) 20	8 / 192 (4.17%) 10	13 / 169 (7.69%) 15
Hepatobiliary disorders Hepatobiliary/Pancreas alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 302 (0.00%) 0	0 / 192 (0.00%) 0	0 / 169 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatology/Skin alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	15 / 302 (4.97%) 36	9 / 192 (4.69%) 15	8 / 169 (4.73%) 18
Endocrine disorders Endocrine alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 302 (0.00%) 0	1 / 192 (0.52%) 2	1 / 169 (0.59%) 1
Musculoskeletal and connective tissue disorders Musculoskeletal/Soft tissue alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	3 / 302 (0.99%) 10	0 / 192 (0.00%) 0	0 / 169 (0.00%) 0
Infections and infestations Infection alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	14 / 302 (4.64%) 17	3 / 192 (1.56%) 3	15 / 169 (8.88%) 19
Metabolism and nutrition disorders			



Albumin alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	4 / 302 (1.32%) 5	2 / 192 (1.04%) 2	1 / 169 (0.59%) 1
Metabolic/Laboratory alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	3 / 302 (0.99%) 4	1 / 192 (0.52%) 2	1 / 169 (0.59%) 2

Non-serious adverse events	Favorable - PET negative (after amendment 2010)	Unfavorable - PET negative (after amendment 2010)	No PET after 2 cycles
Total subjects affected by non-serious adverse events subjects affected / exposed	124 / 185 (67.03%)	232 / 320 (72.50%)	12 / 21 (57.14%)
Vascular disorders			
Vascular alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	5 / 185 (2.70%) 8	5 / 320 (1.56%) 5	2 / 21 (9.52%) 2
Surgical and medical procedures			
Surgery/Intra-operative injury alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 185 (0.00%) 0	0 / 320 (0.00%) 0	0 / 21 (0.00%) 0
General disorders and administration site conditions			
Constitutional Symptoms alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	1 / 185 (0.54%) 1	6 / 320 (1.88%) 6	2 / 21 (9.52%) 2
Immune system disorders			
Allergy/Immunology alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 185 (0.00%) 0	0 / 320 (0.00%) 0	1 / 21 (4.76%) 1
Reproductive system and breast disorders			
Sexual/Reproductive function alternative dictionary used: CTC AE 3.0	Additional description: From clinical database. All AEs (grade 3 or more).		

subjects affected / exposed occurrences (all)	0 / 185 (0.00%) 0	1 / 320 (0.31%) 1	0 / 21 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 185 (0.00%)	19 / 320 (5.94%)	1 / 21 (4.76%)
occurrences (all)	0	24	1
Investigations			
Alkaline phosphatase	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences (all)	0	0	0
ANC	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	107 / 185 (57.84%)	200 / 320 (62.50%)	9 / 21 (42.86%)
occurrences (all)	226	457	23
Bilirubin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	8 / 185 (4.32%)	8 / 320 (2.50%)	0 / 21 (0.00%)
occurrences (all)	76	119	0
GGT	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 185 (0.00%)	6 / 320 (1.88%)	0 / 21 (0.00%)
occurrences (all)	0	8	0
Platelets	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	1 / 185 (0.54%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences (all)	1	0	0
Serum creatinine	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	9 / 185 (4.86%)	8 / 320 (2.50%)	0 / 21 (0.00%)
occurrences (all)	78	119	0
SGOT(ASAT)	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			

subjects affected / exposed	1 / 185 (0.54%)	2 / 320 (0.63%)	0 / 21 (0.00%)
occurrences (all)	1	2	0
SGPT(ALAT)	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	2 / 185 (1.08%)	5 / 320 (1.56%)	0 / 21 (0.00%)
occurrences (all)	3	6	0
White Blood Cells	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	22 / 185 (11.89%)	55 / 320 (17.19%)	2 / 21 (9.52%)
occurrences (all)	30	95	2
Cardiac disorders			
Cardiac Arrhythmia	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	0 / 185 (0.00%)	1 / 320 (0.31%)	0 / 21 (0.00%)
occurrences (all)	0	1	0
Cardiac General	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	2 / 185 (1.08%)	3 / 320 (0.94%)	2 / 21 (9.52%)
occurrences (all)	2	3	3
Cardiovascular	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	2 / 185 (1.08%)	0 / 320 (0.00%)	0 / 21 (0.00%)
occurrences (all)	2	0	0
Nervous system disorders			
Neurology	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	5 / 185 (2.70%)	3 / 320 (0.94%)	0 / 21 (0.00%)
occurrences (all)	5	3	0
Blood and lymphatic system disorders			
Blood/Bone Marrow	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			
subjects affected / exposed	2 / 185 (1.08%)	4 / 320 (1.25%)	0 / 21 (0.00%)
occurrences (all)	2	4	0
Febrile neutropenia	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0			

subjects affected / exposed occurrences (all)	11 / 185 (5.95%) 12	17 / 320 (5.31%) 19	1 / 21 (4.76%) 1
Hemoglobin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	1 / 185 (0.54%) 1	3 / 320 (0.94%) 3	0 / 21 (0.00%) 0
Lymphatics	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 185 (0.00%) 0	0 / 320 (0.00%) 0	0 / 21 (0.00%) 0
Ear and labyrinth disorders			
Auditory/Hearing	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 185 (0.00%) 0	0 / 320 (0.00%) 0	0 / 21 (0.00%) 0
Eye disorders			
Ocular/Visual	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 185 (0.00%) 0	0 / 320 (0.00%) 0	0 / 21 (0.00%) 0
Gastrointestinal disorders			
Gastrointestinal	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	9 / 185 (4.86%) 11	15 / 320 (4.69%) 16	1 / 21 (4.76%) 2
Hepatobiliary disorders			
Hepatobiliary/Pancreas	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	0 / 185 (0.00%) 0	0 / 320 (0.00%) 0	0 / 21 (0.00%) 0
Skin and subcutaneous tissue disorders			
Dermatology/Skin	Additional description: From clinical database. All AEs (grade 3 or more).		
alternative dictionary used: CTC AE 3.0 subjects affected / exposed occurrences (all)	3 / 185 (1.62%) 4	1 / 320 (0.31%) 1	1 / 21 (4.76%) 2
Endocrine disorders			

<p>Endocrine</p> <p>alternative dictionary used: CTC AE 3.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0	0	0
<p>Musculoskeletal and connective tissue disorders</p> <p>Musculoskeletal/Soft tissue</p> <p>alternative dictionary used: CTC AE 3.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0	0	0
<p>Infections and infestations</p> <p>Infection</p> <p>alternative dictionary used: CTC AE 3.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	Additional description: From clinical database. All AEs (grade 3 or more).		
	1 / 185 (0.54%)	9 / 320 (2.81%)	1 / 21 (4.76%)
	1	10	1
<p>Metabolism and nutrition disorders</p> <p>Albumin</p> <p>alternative dictionary used: CTC AE 3.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Metabolic/Laboratory</p> <p>alternative dictionary used: CTC AE 3.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	Additional description: From clinical database. All AEs (grade 3 or more).		
	1 / 185 (0.54%)	5 / 320 (1.56%)	0 / 21 (0.00%)
	1	7	0
	Additional description: From clinical database. All AEs (grade 3 or more).		
	0 / 185 (0.00%)	0 / 320 (0.00%)	0 / 21 (0.00%)
	0	0	0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 December 2011	<p>Purpose: to formalize the agreements with the EORTC IDMC following the pre-planned interim analysis.</p> <p>1) Recruitment in the trial was to continue until 355 patients with FDG-PET positive after two cycles of ABVD were enrolled, in order to be able to answer the second objective of the study.</p> <p>2) All patients (including those randomized in the EXP arm) who were FDG-PET negative after two cycles of ABVD were to receive the standard combined modality treatment arm.</p>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/24637998>